Psilocybin is a naturally occurring psychedelic compound derived from psilocybe mushrooms. It produces an altered state of consciousness lasting approximately six hours. Its therapeutic effects have been explored in relation to:
Research indicates that psilocybin has a low potential for abuse and dependence, making it a promising option for therapeutic use.
Patients who have undergone psilocybin therapy often report enhanced life satisfaction, including increased optimism and peace, contributing to overall well-being.
Clinical studies have shown that psilocybin therapy can provide rapid relief from symptoms of depression and anxiety, often after just a single session.
The therapeutic benefits of psilocybin, such as improved mood and decreased anxiety, have been reported to last for several months following treatment.
As with any drug, psilocybin carries inherent risks. However, these risks are significantly reduced when psilocybin is administered in a controlled, clinical, and supervised environment. The occurrence of side effects can vary widely among individuals, but careful management in therapeutic settings helps minimize these risks.
When used infrequently and under professional supervision, psilocybin is not addictive.
The largest and most significant trial to date regarding psilocybin therapy is the Compass Pathways Phase 2b clinical trial, published in November 2022 in the New England Journal of Medicine. Many patients with treatment resistant depression showed a rapid and significant improvement over placebo in symptoms on day two and at the week three endpoint for the trial with many sustaining benefits over placebo at week 12.
For end-of-life cancer care, 2023 research shows that 70-100% of participants had positive life changes, and 60-80% of participants had reduced anxiety and depression with the same response six months after psilocybin administration.
A 2022 case report indicated significant symptom improvement for an individual with Obsessive Compulsive Disorder (OCD), with improvements continuing and lasting a year later.
A phase I 2023 study explored the use of psilocybin in treating anorexia. It was deemed safe and tolerable with the intention of more research in the future.
A 2015 study demonstrated an 80% adherence to smoking cessation with the use of psilocybin.
Psilocybin is linked to feelings of introspection, euphoria, connectedness, and optimism. Many report:
The most common side effect is feeling nauseous after ingesting psilocybin. Negative experiences, or “bad trips,” characterized by anxiety, fear, or distress, are also possible but can often be mitigated by a supportive setting and professional guidance.
Stay connected.
Sign up for our email newsletter where we share the latest news, education, events, and research in the psychedelic space.
Medicine
Services
If you are in a life threatening situation – don’t use this site.
Text 45645 or Call +1 (833) 456-4566 to get immediate help. Provided by the CMHA
© 2024 Field Trip Health Canada. All Rights Reserved.
EN 
FR